The current migraine treatment landscape is mainly dominated by generic drugs, as the majority of
migraine drugs have seen their patents expire. However current treatments leave a large number of
patients undertreated; many of the drugs, for both acute and preventative treatment, have poor
efficacy profiles which are ineffective in a large number of patients. In addition to this, many of these
drugs are contraindicated in patients with certain co-morbidities.
Current research focuses on using novel mechanisms of action such as CGRP-based receptor and ligand
inhibition, corticotrophin receptor antagonism, and nitrous oxide inhibition. Approval of CGRP
monoclonal antibodies is one of the key developments in the preventive market.
Regionally, Rise in focus of vendors on the emerging markets, such as Asia-Pacific and LAMEA, is
expected to boost the market growth. Asia-Pacific is projected to witness significant growth in future,
owing to rise in demand for better healthcare facilities and improvements in healthcare infrastructure.
Furthermore, this region presents remarkable opportunities for the venture capitalists and investors, as
the developed markets are comparatively saturated.
Major Players profiled in the Migraine Market report incorporate: Abbott Laboratories, Allergan Plc.,
AstraZeneca, Eisai Co., Ltd., Endo International Plc., GlaxoSmithKline Plc., Impax Laboratories, Johnson &
Johnson, Merck & Co., and Pfizer Inc.
Latest Industry News
Allergan plc (NYSE: AGN) today announced that the U.S. Food and Drug Administration (FDA) has
accepted the company's New Drug Application (NDA) for ubrogepant for the acute treatment of
migraine in adults. The NDA filing is based on the successful completion of four clinical trials – two
pivotal studies, ACHIEVE I and ACHIEVE II, which demonstrated the efficacy, safety and tolerability of
ubrogepant, as well as two additional safety studies. A 10-month review period has been assigned with
the Prescription Drug User Fee Act (PDUFA) in the fourth quarter of 2019.
"Following the acceptance and expected review of this NDA, we anticipate ubrogepant to be the first
approved oral CGRP receptor antagonist for the acute treatment of migraine, and may be used in
conjunction with other available migraine treatments," said David Nicholson, Chief Research and
Development Officer, Allergan. "As a leader in Chronic Migraine research for more than 20 years,
Allergan looks to provide options for patients who need new acute and preventative treatments for
migraine.
Request a Discount on standard prices of this premium report @
https://www.businessindustryreports.com/check-discount/163005 .
Region segment: This report is segmented into several key regions, with sales, revenue, market share
(%) and growth Rate (%) of Migraine in these regions, from 2014 to 2023 (forecast), covering: North
America, Europe, Asia Pacific, Middle East & Africa and South America.
Significant points in table of contents: Market Definition, Market Overview, Business Introduction,
Segmentation (Region Level), Segmentation (Type Level), Segmentation (Industry Level), Segmentation